Related Experiment Video
Updated: May 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Diaphragmatic rupture, a new complication of Bevacizumab
Introduction:
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor has demonstrated a significant benefit on overall survival (OS) and progression free survival (PFS) in patients with metastatic colorectal carcinoma. Many adverse effects of Bevacizumab are well-known. We report here the first case of diaphragmatic perforation after Bevacizumab treatment.
Patients And Methods:
A case of Bevacizumab induced diaphragmatic perforation was reported and a search of PubMed and Cochrane databases was performed in order to review relevant literature on the adverse effects of Bevacizumab.
Discussion:
Serious late surgical complications may occur even if the delay between surgery and Bevacizumab treatment is respected. These complications may be life threatening for patients, and demonstrate the importance of careful monitoring after postoperative administration of Bevacizumab.
More Related Videos
Related Concept Videos
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax II: Pathophysiology
Aneurysm III: Interprofessional Care
Esophageal Perforation-I: Introduction
The location of esophageal perforation can vary, occurring anywhere along the esophagus.
Pneumothorax-II
Clinical Manifestations:
Esophageal Perforation-II: Clinical Manifestations and Management
Clinical Manifestations:
